Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes

Anticancer Research

Volumn 28, Issue 1 B, 2008, Pages 379-387

  Kondo, Hiroshi ^a   Hazama, Shoichi ^a   Kawaoka, Toru ^a   Yoshino, Shigefumi ^a   Yoshida, Shin ^a   Tokuno, Kazuhisa ^a   Takashima, Motonari ^a   Ueno, Tomio ^a   Hinoda, Yuji ^a   Oka, Masaaki ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CTL; Dendritic cell; Immunotherapy; MUC1; Pancreatic cancer

Indexed keywords

GLYCOPROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; MITOMYCIN C; MUCIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ARTICLE; CELL DIFFERENTIATION; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; FOLLOW UP; GLYCOSYLATION; HUMAN; LUNG METASTASIS; PANCREAS CANCER; PRIORITY JOURNAL; PRURITUS; RECURRENT CANCER; T LYMPHOCYTE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CA-15-3 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 40549097760     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Hirata K, Sato T, Mukaiya M, Yamashiro K, Kimura M, Sasaki K and Denno R: Results of 1001 pancreatic resections for invasive ductal adenocarcinoma of the pancreas. Arch Surg 132: 771-776, 1997.
2. Gudjonsson B: Cancer of the pancreas. 50 years of surgery. Cancer 60: 2284-2303, 1987.
3. Warshaw AL and Swanson RS: Pancreatic cancer in 1988. Possibilities and probabilities. Ann Surg 208: 541-553, 1988.
4. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB and Abrams RA: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 226: 248-257, 1997.
5. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Kloppel G, Dhaene K and Michelassi F: Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 228: 508-517, 1998.
6. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H and Buchler MW: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91: 586-594, 2004.
7. Buchler M, Friess H, Schultheiss KH, Gebhardt C, Kubel R, Muhrer KH, Winkelmann M, Wagener T, Klapdor R and Kaul M: A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer 68: 1507-1512, 1991.
8. Friess H, Gassmann M and Buchler MW: Adjuvant therapy of pancreatic cancer using monoclonal antibodies and immune response modifiers. Int J Pancreatol 21: 43-52, 1997.
9. Hersh EM, Metch BS, Muggia FM, Brown TD, Whitehead RP, Budd GT, Rinehart JJ, Crawford ED, Bonnet JD and Behrens BC: Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience. J Immunother 10: 426-431, 1991.
10. Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel M and Finn OJ: Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 54: 254-264, 2005.
11. Yamamoto K, Mine T, Katagiri K, Suzuki N, Kawaoka T, Ueno T, Matsueda S, Yamada A, Itoh K, Yamana H and Oka M: Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer. Oncol Rep 13: 874-883, 2005.
12. Sparano JA, Fisher RI, Weiss GR, Margolin K, Aronson FR, Hawkins MJ, Atkins MB, Dutcher JP, Gaynor ER and Boldt DH: Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. J Immunother Emphasis Tumor Immunol 16: 216-223, 1994.
13. Oka M, Suzuki M, Hazama S and Suzuki T: Adoptive immunotherapy for unresectable or recurrent pancreatic cancer, using lymphocyte-activated killer cells or cytotoxic T cells. J Hep Bil Pancr Surg 2: 163-167, 1994.
14. Yamamoto K, Ueno T, Kawaoka T, Hazama S, Fukui M, Suehiro Y, Hamanaka Y, Ikematsu Y, Imai K, Oka M and Hinoda Y: MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res 25: 3575-3580, 2005.
15. Suzuki N, Maeda Y, Tanaka S, Hida N, Mine T, Yamamoto K, Oka M and Itoh K: Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer. Int J Cancer 98: 45-50, 2002.
16. Devine PL and McKenzie IF: Mucins: structure, function, and associations with malignancy. Bioessays 14: 619-625, 1992.
17. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN and Wilson D: Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265: 15286-15293, 1990.
18. Hanisch FG, Stadie TR, Deutzmann F and Peter-Katalinic J: MUC1 glycoforms in breast cancer - cell line T47D as a model for carcinoma-associated alterations of O-glycosylation. Eur J Biochem 236: 318-327, 1996.
19. Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R and Lamport D: Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 47: 5476-5482, 1987.
20. Barnd DL, Lan MS, Metzgar RS and Finn OJ: Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86: 7159-7163, 1989.
21. Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, Bast RC Jr and Finn OJ: Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 51: 2908-2916, 1991.
22. Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT and O'Brian CA: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu protooncogene. Cell Immunol 151: 225-234, 1993.
23. Byrd JC, Ho JJ, Lamport DT, Ho SB, Siddiki B, Huang J, Yan PS and Kim YS: Relationship of pancreatic cancer apomucin to mammary and intestinal apomucins. Cancer Res 51: 1026-1033, 1991.
24. Osako M, Yonezawa S, Siddiki B, Huang J, Ho JJ, Kim YS and Sato E: Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors. Cancer 71: 2191-2199, 1993.
25. Hollingsworth MA, Strawhecker JM, Caffrey TC and Mack DR: Expression of MUC1, MUC2, MUC3 and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines. Int J Cancer 57: 198-203, 1994.
26. Masaki Y, Oka M, Ogura Y, Ueno T, Nishihara K, Tangoku A, Takahashi M, Yamamoto M and Irimura T: Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma. Hepatogastroenterology 46: 2240-2245, 1999.
27. Yamamoto K, Yahara N, Gondo T, Ishihara T and Oka M: Establishment and characterization of a new human pancreatic cancer cell line, YPK-1. Bull Yamaguchi Med Sch 49: 33-42, 2002.
28. Kawaoka T, Takashima M, Yamamoto K, Ueno T and Oka M: Adoptive Immunotherapy using MUC1-specific CTLs for unresectable pancreatic cancer. Nippon Rinsho 64: 279-282, 2006. (In Japanese.)
29. Palucka K and Banchereau J: Dendritic cells: a link between innate and adaptive immunity. J Clin Immunol 19: 12-25, 1999.
30. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B and Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811, 2000.
31. Pulendran B, Banchereau J, Maraskovsky E and Maliszewski C: Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 22: 41-47, 2001.
32. DeMatos P, Abdel-Wahab Z, Vervaert C and Seigler HF: Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol 185: 65-74, 1998.
33. Fields RC, Shimizu K and Mule JJ: Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95: 9482-9487, 1998.
34. Timmerman JM and Levy R: Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 50: 507-529, 1999.
35. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P: CTCAE v3.0 development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003.
36. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
37. Yamaguchi Y, Ohshita A, Kawabuchi Y, Ohta K, Shimizu K, Minami K, Hihara J, Miyahara E and Toge T: Adoptive immunotherapy of cancer using activated autologous lymphocytes - current status and new strategies. Hum Cell 16: 183-189, 2003.
38. Sobin LH and Wittekind C: TNM classification of Malignant Tumors, 6th edition. New York. UICC, Wiley-Liss, pp. 93-93, 2002
39. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K and Yachi A: Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 153: 2102-2109, 1994.
40. Kotera Y, Fontenot JD, Pecher G, Metzgar RS and Finn OJ: Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54: 2856-2860, 1994.
41. Musselli C, Ragupathi G, Gilewski T, Panageas KS, Spinat Y and Livingston PO: Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer 97: 660-667, 2002.
42. Pecher G, Haring A, Kaiser L and Thiel E: Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 51: 669-673, 2002.
43. Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF and Mitchell PL: Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 12: 869-877, 2006.
44. Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, Hantschel M, Brugger W, Schroder S, Horger MS, Kanz L and Brossart P: Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66: 5910-5918, 2006.
45. Marincola FM, Drucker BJ, Keeling CA, Siao DY, Starnes HF Jr, Goodwin DA and Holder WD Jr.: The in vivo distribution of human peripheral blood lymphocytes and lymphokine-activated killer cells adoptively transferred in human pancreatic cancer-bearing nude mice. Surgery 105: 79-85, 1989.
46. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L and Brugger W: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96: 3102-3108, 2000.
47. Zhou LT and Tedder TF: Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 154: 3821-3835, 1995.
48. + blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 93: 2588-2592, 1996.
49. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
50. Bramhall SR, Rosemurgy A, Brown PD, Bowry C and Buckels JA: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19: 3447-3455, 2001.
51. Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, Formica V, Giorgi G, Bonmassar E and Francini G: Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol 175: 820-828, 2005.